RubrYc Therapeutics is a preclinical precision oncology company that uses a proprietary engineering approach to discover novel cancer medicines. The Company’s platform leverages machine learning to discover a novel class of antigens which are used to steer antibody discovery to prescribed epitopes. Our most advanced project has demonstrated in vivo efficacy superior to benchmarks as presented at the American Academy of Cancer Research last year and repeated in multiple models. The Company is engaging co-discovery partners and is raising Series B to go to clinic.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
anti-CD25 mAb driving Treg depletion to restore tumor immunity
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):